15 Jul Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation

Paris, France and Camberley, UK – 15 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s exsig™ COVID-19 Direct Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).

https://novacyt.com/wp-content/uploads/2022/07/Novacyt-CTDA-approval-of-Exsig-Direct.pdf